Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study-Reference-Cited by-同舟云学术

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

Published:2019-06 Issue:6 Volume:6 Page:e295-e305
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Pipe Steven W,Shima Midori,Lehle Michaela,Shapiro Amy,Chebon Sammy,Fukutake Katsuyuki,Key Nigel S,Portron Agnès,Schmitt Christophe,Podolak-Dawidziak Maria,Selak Bienz Nives,Hermans Cedric,Campinha-Bacote Avrita,Kiialainen Anna,Peerlinck Kathelijne,Levy Gallia G,Jiménez-Yuste Victor

Publisher

Elsevier BV

Subject

Hematology

Reference33 articles.

1. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators;Soucie;Am J Hematol,1998

2. The hemophilias—from royal genes to gene therapy;Mannucci;N Engl J Med,2001

3. Guidelines for the management of hemophilia;Srivastava;Haemophilia,2013

4. Hemophilia A in the third millennium;Franchini;Blood Rev,2013

5. The current status of prophylactic replacement therapy in children and adults with haemophilia;Ljung;Br J Haematol,2015

Cited by 288 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies;Expert Review of Hematology;2024-09-12

2. Perioperative Management for Port Catheter Procedures in Pediatric Patients with Severe Hemophilia and Inhibitors;Hämostaseologie;2024-09-12

3. Hämophilie – Revolution der Therapiemöglichkeiten?;Die Innere Medizin;2024-08-30

4. Normalisation of Haemostasis in Haemophilia A;EMJ Hematology;2024-07-25

5. Emicizumab Prophylaxis in Children and Adolescents with Hemophilia A;Indian Journal of Pediatrics;2024-07-18